http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29771707

Outgoing Links

Predicate Object
contentType Journal Article|Published Erratum
endingPage 2072
issn 1538-7445
0008-5472
issueIdentifier 10
pageRange 2072-2072
publicationName Cancer Research
startingPage 2072
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06aba5a94448c92faf09747c7e7c67bd
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b470728a65ee937568d6572be1f55f8f
bibliographicCitation Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2020 May 15;80(10):2072. doi: 10.1158/0008-5472.can-20-0768. PMID: 32414837.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61fbcfbff0731fb802413a8d60ed4684
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a22c953d1466a545d220f5770c80b41
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60ebd39b0747bb55e6c960134d371f1c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b0675d3efdec002b52d7f5913c7c67f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3278699f7aba13e0d81dc2875dcf9b21
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b14a512af0c528e46436d7248024bcdc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b17dba62e24cf0184cffa0fbf5429468
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_139739a00f3a95ce83b1e2b2e89f3141
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b6150b6bc4fae9a82a5ebd3c32c26ad
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0171609f48e7a26d702ba5153823aa93
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fcd5f93d9403f8a2c6813e65cd093e86
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_990093611b33fbfa2ed855c6855510fe
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce820bc3729125724a01eaf0da8b2fd5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff3346e222983063a43928d2e8042397
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e1cdce104321a003ca1f52c627e9f5d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1972-7798
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d4dee2ff736b4c9202cee1e52d5ed9b
date 2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1158/0008-5472.can-20-0768
https://pubmed.ncbi.nlm.nih.gov/32414837
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2786
https://portal.issn.org/resource/ISSN/0008-5472
https://portal.issn.org/resource/ISSN/1538-7445
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d7ecf8c06ccd27f738eab5f001875b5e
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15951529
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f4b26d81e6b84e466752e84f0e9b347d

Total number of triples: 43.